Exelixis | EXEL - Cost Of Sales


Exelixis reported $19.95M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
Amgen USD 1.6B 187M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Bayer EUR 5.23B 731M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Cytokinetics USD 160K 104.24M Mar/2026
Eisai JPY 52.02B 931M Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Exelixis USD 19.95M 6.53M Mar/2026
Genmab DKK 81M 23M Dec/2025
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Incyte USD 104.5M 16.68M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
MacroGenics USD 10.12M 34.18M Dec/2025
Merck USD 2.94B 380M Mar/2026
Moderna USD 955M 503M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sanofi EUR 3.76B 344M Dec/2025
Takeda JPY 560.54B 159.39B Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Xencor USD 61.66M 50.95M Jun/2025